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Ochratoxin A (OTA) is a ubiquitous mycotoxin with potential nephrotoxic, carcinogenic, and cytotoxic 
action. It has been proposed that OTA might be involved in the development of Balkan endemic nephropathy, 
which is associated with an increased risk of urinary tract tumours, and of other forms of interstitial 
nephritis. Cell susceptibility to OTA mainly depends on mycotoxin concentrations, duration of exposure, 
and intracellular molecular and genetic context. OTA can affect a cell by stimulating or inhibiting certain 
signalling pathways such as mitogen-activated protein kinase (MAPK). Three major mammalian MAPKs 
have been described: extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), 
and p38 MAPK. All MAPKs regulate diverse cellular programmes, but in most cases ERKs have been 
linked to cell survival, while JNKs, and p38 MAPKs have been implicated in cell death by apoptosis. This 
review looks into OTA-mediated MAPK activation and its effects.
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OCHRATOXIN A: A HAZARDOUS 
MYCOTOXIN
Ochratoxin A (OTA) is a naturally occurring 
mycotoxin produced by several species of Aspergillus 
and Penicillium. OTA has been detected in a variety 
of animal chow and human food, especially in cereals, 
wine, coffee, spices, beer, poultry, and pork. The 
importance of OTA for human health arises from its 
widespread occurrence and the resulting high risk of 
exposure. The highest levels of OTA in food were 
found in Europe, Eastern in particular. However, 
OTA-containing food was also detected in North and 
South America, Asia, and Africa (1). The average 
daily intake of an adult European is 1.044 ng kg-1 
body weight, although the intake can be as high as 
3.55 ng kg-1 b.w. (2). Once ingested, OTA is rapidly 
reabsorbed in the jejunum. In the gastrointestinal 
tract, OTA is hydrolysed to some extent to a less 
toxic derivative ochratoxin α (OTα), and 1 % to 
4 % of OTA is hydroxylated and conjugated in liver 
cells. However, these important processes need 
further clariﬁ cation (3). According to the European 
survey conducted by Miraglia et al. (2), mean plasma 
concentration of OTA in adults is 0.875 nmol L-1, and 
ranges from 0.53 nmol L-1 to 2.75 nmol L-1. OTA 
half-life in serum ranges from 120 h in rats to 840 h in 
monkeys and humans (4, 5). This prolonged retention 
in serum is the consequence of strong binding to 
serum proteins, mainly to albumin. Therefore, less 
than 0.2 % of OTA is free and able to leave blood 
vessels or undergo glomerular ﬁ ltration. The fraction 
of OTA bound to proteins constitutes a mobile reserve 
of OTA that can be released into the tissues as soon 
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as free OTA fraction decreases. Both biliary and 
renal routes are involved in the excretion of OTA 
in rats and mice, but the biliary route prevails (6). 
However, in humans and nonhuman primates (vervet 
monkeys), OTA is excreted mainly via the kidney (7, 
8). It is excreted in the kidney tubules by means of 
organic anion transporters (OATs), and OATs or other 
transporters mediate its reabsorption in all nephron 
segments. This delays elimination and increases the 
risk of OTA accumulation in tissues (9, 10).
OTA has become a human health issue since the 
suspicion that it is involved in the development of 
Balkan endemic nephropathy (BEN) (6, 11, 12), a 
disease associated with an increased risk of urinary 
tract tumours (13), and the development of other 
forms of interstitial nephritis (14, 15). Apparently, the 
aetiology of half the end-stage renal diseases (ESRDs) 
is unknown, and there is a consensus that mycotoxins 
such as OTA might play an important role in these 
cases (16).
In a variety of animal models OTA has produced 
a wide array of toxicological effects, including 
nephrotoxicity, nephrocarcinogenicity, neurotoxicity, 
and immunotoxicity (17, 18).
Numerous studies have tried to elucidate the 
mechanisms implicated in OTA toxicity (9, 17, 19). 
The OTA molecule consists of a dihydroisocoumarin 
moiety that is amide-linked to the L-phenylalanine 
moiety (Figure 1) which is a structural analogue of 
phenylalanine (Phe). This is why OTA can act on all 
metabolic systems involving Phe. It was suggested 
Therefore, an indirect toxic effect of OTA is that it 
changes carbohydrate metabolic pathways. In addition, 
the Phe moiety of OTA can bind to and inhibit Phe 
hydroxylase, and thus impair hydroxylation of Phe 
to tyrosine, which is the key regulatory step in the 
catabolism of this amino acid (19). However, all this 
can not explain the diversity of its toxic effects, such 
as lipid peroxidation, DNA damage, and disruption 
of calcium homeostasis. Several studies suggest that 
OTA toxicity involves oxidative stress (20-23).
It seems that OTA-mediated effects mainly depend 
on mycotoxin concentrations, duration of exposure 
(acute and chronic), and the type of the affected cell. 
As OTA inhibits protein synthesis at relatively high 
doses, which are not seen in everyday exposure, these 
effects have only a minor toxicological relevance. 
However, Gekle et al. (5) have suggested that in the 
low-dose range (naturally occurring exposure) OTA 
interacts with key cell targets, changing the signalling 
pathways. These changes affect the cell function, and 
may disturb the whole-organism homeostasis. One of 
these changes is OTA-induced activation of mitogen-
activated protein kinases (MAPK) reported by several 
studies (6, 24-28).
MAPK FAMILY TREE
The MAPK superfamily of serine/threonine kinases 
is activated by a number of extracellular stimuli, and is 
involved in signal transduction pathways, that play an 
important regulatory role in cell survival and death.
A MAPK cascade includes at least three kinases: a 
MAPK kinase kinase (MKKK), which phosphorylates 
and activates a dual-speciﬁ city MAPK kinase (MKK), 
which in turn activates MAPK by phosphorylating 
adjacent threonine and tyrosine residues within 
their activation loop. Once activated, MAPK can 
affect a number of cytosolic components through its 
proline-directed serine/threonine activity, or it can 
translocate to the nucleus where it can phosphorylate 
and activate a number of transcription factors involved 
in immediate early gene expression (29-31). MAPKs 
are inactivated by a variety of dual-specificity 
phosphatases called MAP kinase phosphatases or 
MKPs. Most of the MKPs can act on a number of 
MAPKs (32, 33). Generally, the antagonistic interplay 
between a kinase and phosphatase needs to be ﬁ nely 
tuned to ensure proper activation of the target protein. 
It has recently been demonstrated that kinases 
control signal amplitude, whereas phosphatases 
Figure 1 Molecular structure of ochratoxin A
that competitive inhibition of Phe-tRNA synthase by 
OTA is the primary cause of OTA toxicity. It stops 
amino-acylation and peptide elongation, and disrupts 
protein synthesis at the post-transcriptional level. 
Since OTA disrupts protein synthesis, it impairs the 
activity of several cellular enzymes, and particularly 
of cytosolic phosphoenolpyruvate carboxykinase, 
which results in a signiﬁ cant drop in gluconeogenesis. 
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mediate both signal amplitude and signal duration. 
Reversible phosphorylation of MAPKs emphasizes the 
importance of the balance between phosphorylating 
kinases and dephosphorylating phosphatases in 
regulating these pathways (34, 35).
Three major mammalian MAPKs have been 
described: extracellular signal-regulated protein 
kinase (ERK), c-Jun N-terminal kinase (JNK) and 
p38 MAPK (Figure 2).
Glu-Tyr sequence, ERK1 and ERK2 can catalyse the 
transfer of a phosphate group to a number of cytosolic 
target molecules such as phospholipase A
2
, the tail 
of the epidermal growth factor receptor, cytoskeletal 
elements, the MAPK-activated protein kinase-2 and 
-3 (MAPKAP-K2, MAPKAP-K3), and p90RSK 
protein kinase, which can translocate to the nucleus 
and phosphorylate transcription factors. In addition, 
activated ERK1 and ERK2 can translocate to the 
nucleus, where they can phosphorylate transcription 
factors such as Elk-1, SAP-1, c-Myc, and ATF-2 
(29-31, 39).
It is crucial that the ﬁ nely concerted interaction 
between kinases and phosphatases regulating the 
ERK1/2 signalling cascade remains undisturbed, as the 
strength and duration of the signal determine whether 
the cell will differentiate or proliferate.
The stress managers: JNK and p38
Members of the MAPK superfamily JNK and p38, 
often jointly referred to as stress kinases, are activated 
in response to proinﬂ ammatory cytokines, growth 
factors, and various environmental stresses (oxidative 
stress, UV irradiation, heat, and osmotic shock). 
Whereas ERK1/2 are primarily involved in cellular 
survival, JNK and p38 appear to be intimately linked 
with programmed cell death. JNK and p38 MAPK are 
activated through two distinct signalling pathways.
JNK family includes three isoforms: JNK1, 
JNK2, and JNK3. JNK1 and JNK2 are ubiquitous, 
and JNK3 is more speciﬁ c to the brain, heart, and 
testis. The immediate upstream JNK kinases are 
MKK4 and MKK7. MKK7 preferentially targets 
threonine 183 and MKK4 phosphorylates tyrosine 
185 in the consensus sequence Thr-Pro-Tyr within 
the JNK activation loop. On the other hand, MKK4/7 
are activated by a large group of MKKKs, usually 
stimulated by GTPases of the Ras or Rho family. 
After translocation to the nucleus, activated JNK can 
phosphorylate a number of transcription factors such 
as c-Jun, ATF-2, and Elk-1, leading to the transcription 
of immediate early genes that dictate short-term and 
long-term response to cell stress (40, 41).
The p38 MAPK family has four isoforms, α, β, γ, 
and δ, differently expressed throughout the organism. 
p38α and p38β have a wide expression pattern. 
p38γ is expressed in skeletal muscle, whereas p38δ 
is detected in small intestine, pancreas, testis, and 
kidney. MKK4, a well known activator of JNK, has 
been shown to phosphorylate p38 in vitro and when 
overexpressed in situ (42); however, it remains to 
Figure 2 Biological effects of the MAPK signalling cascade
The sisters of mercy: ERK1 and ERK2
ERK, the longest known and best characterised 
member of the MAPK family, has a number of 
isoforms (ERK1-5 and ERK7/8). By far the most 
studied are ERK1, 2, and 5 (36). ERK1 and ERK2 
are activated mainly in response to growth and 
differentiation factors. These factors often act through 
the activation of receptor tyrosine kinases (RTK) 
that ultimately lead to the activation of the GTP-
binding protein Ras, which can bind to and activate 
serine/threonine kinase Raf (MKKK). Raf in turn 
phosphorylates and activates dual-speciﬁ city kinases 
MEK1 and MEK2 (MKKs), whose only known 
substrates are ERK1 and ERK2 (37). ERK2 has been 
shown to phosphorylate MEK1 in vitro (38). Although 
in vivo phosphorylation of MEK1 by ERK2 is yet 
to be demonstrated, this suggests that ERK2 could 
participate in its activation in a positive feedback 
loop. Following dual phosphorylation in the Thr-
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be determined if under normal operating conditions 
p38 is in fact a substrate for MKK4. Activation of 
MEKK1, the MKK4 upstream regulator, does not lead 
to the activation of the p38 signalling pathway (38). 
MKK3 and MKK6 have been identiﬁ ed as essential 
dual-speciﬁ city kinases that phosphorylate threonine 
and tyrosine residues of the Thr-Gly-Tyr motif of p38. 
The major cytosolic targets for p38 are serine protein 
kinases MAPKAP-K2 and MAPKAP-K3, known to 
activate heat shock protein 27 (hsp27) and cyclic AMP 
response element binding protein (CREB). In addition, 
p38 MAPK can translocate to the nucleus where it can 
phosphorylate several transcription factors such as 
ATF-2, Elk-1, and Max. p38 has also been linked to 
the regulation of cytokine production (29, 43).
CLOSE INTERPLAY BETWEEN OTA AND 
MAPKS
Although it has been reported that possible targets 
of OTA are the liver, the immune system, and the 
brain cells, the kidney is the main target of OTA. 
Chronic OTA exposure leads to impairment of the 
renal function and morphology and to increased 
incidence of renal adenoma and carcinoma. Several 
studies have demonstrated direct association between 
MAPK-stimulated cell proliferation and renal cancer 
development (44, 45). A number of organ tumours, 
including about 50 % of all renal neoplasias, have 
shown increased ERK1/2 activation (45). On the other 
hand, JNK might play a role in both tumour growth 
and tumour suppression (46). Most of the signalling 
cascades have both pro-survival and pro-death 
function. This ability to mediate diverse responses 
depends on factors such as the nature and intensity of 
the stimulus and cellular context.
It has been shown that OTA may induce cell 
death. In most cases cells die either by necrosis or 
apoptosis. Apoptosis is an organised, genetically 
directed process, also known as programmed cell 
death. Apoptosis allows the organism to control cell 
number and tissue size, and to protect itself from 
rogue cells that threaten homeostasis. Changes in 
gene activity may switch on cell self-destruction 
programme. Morphologically, programmed cell death 
is characterised by cell shrinking, membrane blebbing, 
and eventually fragmentation into membrane-bound 
apoptotic bodies. During apoptosis, the cell membrane 
loses its asymmetry, and phosphatidylserine (PS) 
appears on the cell surface. This is the “eat me” signal 
for macrophages to clear the body of apoptotic cell 
without inﬂ ammation of the surrounding tissue (47, 
48).
In contrast to apoptosis, necrosis has been 
considered an uncontrolled form of cell death. 
Morphologically, necrosis is characterised by 
vacuolization of the cytoplasm, loss of membrane 
integrity, and cellular swelling. The resulting release 
of intracellular components into the microenvironment 
can provoke inﬂ ammatory response (47, 48).
Several in vitro and in vivo studies have suggested 
that OTA induces necrosis or apoptosis, depending 
mainly on OTA concentration. In most cases, high 
OTA concentrations (>1 μmol L-1) cause necrosis of 
renal cells (both of proximal tubular and collecting 
duct origin), as demonstrated by lactate dehydrogenase 
(LDH) release (5, 49). In contrast, at low nanomolar 
concentrations, OTA stimulates apoptosis, which 
has been conﬁ rmed by chromatin condensation and 
fragmentation (DAPI staining, haematoxylin/eosin 
staining), DNA fragmentation (TUNEL assay, 
diphenylamine method), DNA ladder formation (DNA 
electrophoresis on agarose gel), and/or apoptotic 
enzyme caspase-3 activation (5, 26, 28, 50). In 
addition, at 1 μmol L-1, OTA was associated with 
both types of cell death (5, 26, 28). These effects also 
appear to be cell-speciﬁ c, which might explain why 
certain epithelial cell types along the nephron differ 
in susceptibility to OTA.
The exact mechanisms leading to OTA-induced 
necrosis or apoptosis remain unknown. Horvath 
et al. (25) have shown that OTA stimulates lipid 
peroxidation, followed by enhanced membrane 
permeability. In addition, OTA competitively inhibits 
some transport proteins and enzymes located in the 
inner mitochondrial membrane (ATPase, succinate 
dehydrogenase, and cytochrome c oxidase). These 
might inhibit mitochondrial respiration and ATP 
production, leading to ATP depletion within a cell. 
Both of these actions might contribute to OTA-
mediated necrosis. It also seems that cell death by 
necrosis is associated with impaired macromolecule 
synthesis caused by OTA concentrations ≥1 μmol L-1 
(51). OTA-mediated inhibition of protein synthesis 
may prevent the expression of enzymes involved in 
defence and repair mechanisms, triggering and/or 
potentiating other adverse effects of OTA (52).
Changes in the regulation of cell survival contribute 
to the development of many human diseases. Increased 
rate of apoptosis in the kidney may lead to polycystic 
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kidney disease, glomerular sclerosis, or interstitial 
fibrosis (53-55). These damages were found in 
porcine nephropathy and BEN. This is why Mantle 
et al. suggested that apoptosis might play a role in the 
aetiology of BEN (56).
It has been shown that MAPKs are key components 
of cell survival/death pathways. Gekle et al. (26, 27) 
investigated the effects of OTA in two clones of 
MDCK kidney cells, MDCK-C7 and MDCK-C11, 
resembling principal cells and intercalated cells of 
the collecting duct, respectively. In MDCK-C11 cells, 
nanomolar OTA concentrations provoked primarily 
necrosis and in MDCK-C7 cells apoptosis. This 
conﬁ rms different sensitivity of cells to OTA. ERK1/2 
and JNK1/2 were activated in MDCK-C7 cells, but not 
in MDCK-C11 cells. The authors suggested that JNK 
signalling pathway might play a role in OTA-induced 
MDCK-C7 cell apoptosis.
Some other studies also confirmed OTA-
induced MAPK phosphorylation (5, 24, 25, 28). 
Phosphorylation of ERK1/2 and of their substrates 
Elk-1 and p90RSK was observed in kidney samples 
of male Fischer 344 rats fed with a carcinogenic dose 
of OTA over 7 days, 21 days, and 12 months (24). 
OTA was found to increase phosphorylation of all 
three major MAPKs (ERK, JNK and p38) in renal 
proximal tubule cell lines (OK, NRK-52E and LLC-
PK1 cells) (5, 28).
ERK and JNK/p38 activation could exert both 
protective and adverse effects. However, in most 
cases ERKs have been linked with cell survival and 
JNK/p38 with inhibition of cell growth and apoptosis 
(57). It was suggested that a dynamic balance between 
the anti-apoptotic ERK pathway and the pro-apoptotic 
JNK/p38 pathways determines whether a cell will 
survive or undergo apoptosis (57).
What can also greatly inﬂ uence a speciﬁ c biological 
response is the duration of MAPK activation. 
Transient ERK activation induced cell proliferation 
and sustained activation cell differentiation (58). 
Sustained ERK activation is associated with nuclear 
translocation and phosphorylation of transcription 
factors (59, 60). Therefore, in contrast to transient 
activation, sustained activation might have a different 
effect on gene expression (58). It has also been reported 
that the duration of JNK activation is decisive for the 
cell fate; transient activation leads to cell proliferation 
or differentiation, and prolonged activation leads to 
apoptosis (61-63).
The actual molecular mechanism responsible 
for OTA-mediated activation of MAPK cascades 
has not yet been elucidated. However, it seems to 
involve oxidative stress. Reactive oxygen species 
(ROS) or redox disturbances stimulate redox-sensitive 
signalling molecules such as MAPKs and modify 
expression of various genes.
Under normal physiological conditions, apoptosis 
signal-regulating kinase 1 (ASK1), a kinase that 
activates JNK and p38 by direct site-specific 
phosphorylation of their respective upstream kinases, is 
inhibited by thioredoxin, glutaredoxin, or glutathione-
S-transferase (GST)μ, while GSTp inhibits JNK. 
However, suppression of ASK1 and JNK activities 
by these molecules is reversed by oxidative stress, 
which could be induced by OTA. The association 
between thioredoxin and ASK1 gives rise to a dimer 
thioredoxin/ASK1, which inactivates ASK1. ROS 
were found to oxidise thioredoxin reactive thiol groups 
and to cause disulﬁ de bridge formation within the 
thioredoxin molecule, which destabilizes the dimer. As 
a result, ASK1 can escape from thioredoxin inhibition 
and become multimerised, which corresponds to the 
active form of the enzyme. Follows downstream 
activation of JNK and/or p38. ASK1 inhibition by 
glutaredoxin or GSTμ takes place in the thioredoxin-
like manner. In addition, JNK activation is inhibited 
by its binding to GSTp, and ROS dissociates the 
GSTp/JNK complex by oxidation of GSTp cysteine 
residues, leading to formation of GSTp dimers and/or 
multimers and phosphorylation of JNK (64-66).
On the other hand, it is also possible that OTA 
affects MAPK activation by downregulating their 
specific phosphatases through increased ROS 
production. Protein tyrosine phosphatases, including 
MKPs, have a conserved cysteine residue within their 
catalytic domain, and this critical cysteine can be 
oxidised, leading to a reversible loss of phosphatase 
function (67).
It must be emphasised that, depending on cell type 
and doses involved, oxidative stress may lead either 
to cell death or considerable DNA damage/mutations, 
which in turn may end in cell transformation and 
tumour development (68).
In conclusion, a combination of the basic 
mechanisms of action of OTA (and of active OTA 
derivatives and conjugates capable to react with 
cellular macromolecules including DNA) discussed 
in this review and its long plasma half-life could 
partly explain the cytotoxicity, genotoxicity, and 
carcinogenicity of OTA. MAPKs certainly have a 
role in these processes. However, it would be too 
pretentious to consider them the most important 
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players in multiple OTA toxic effects, and most 
certainly many other molecules, some of them yet to 
be identiﬁ ed, are contributing to the complex network 
of OTA action.
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Sažetak
PUTOVANJE KROZ INTERAKCIJE PROTEINSKIH KINAZA AKTIVIRANIH MITOGENIMA I 
OKRATOKSINA A
Okratoksin A (OTA) posvuda je prisutan mikotoksin za koji se smatra da je potencijalno nefrotoksičan i 
karcinogen, a može uzrokovati i smrt stanice. OTA se smatra mogućim uzročnikom balkanske endemske 
nefropatije koju karakterizira povećani rizik od razvoja tumora mokraćnog sustava te različitih drugih vrsta 
intersticijskog nefritisa. Osjetljivost stanice naspram OTA ovisi ponajprije o koncentraciji mikotoksina, 
vremenu izloženosti i o unutarstaničnome molekularnom i genskom sklopu. OTA može djelovati na stanicu 
tako što potiče ili inhibira određene signalne putove u stanici poput puta proteinskih kinaza aktiviranih 
mitogenima (MAPK). Tri glavne MAPK u sisavaca su proteinska kinaza regulirana izvanstaničnim 
signalima (ERK), kinaza koja fosforilira N-kraj transkripcijskog faktora c-Jun (JNK) i p38 MAPK. 
Svi članovi porodice MAPK reguliraju različite stanične programe, s time da ERK najčešće stimuliraju 
preživljavanje stanica, dok JNK i p38 MAPK najčešće uzrokuju umiranje stanica apoptozom. U ovome smo 
preglednom članku prikazali na koji način stanice odgovaraju na aktivaciju MAPK koju potiče OTA.
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